Tejas Savant
Stock Analyst at Morgan Stanley
(2.35)
# 2,629
Out of 4,981 analysts
233
Total ratings
43.94%
Success rate
-1.59%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Overweight | $65 → $68 | $85.13 | -20.12% | 4 | Aug 12, 2025 | |
| TXG 10x Genomics | Maintains: Overweight | $18 → $17 | $13.35 | +27.34% | 15 | Aug 12, 2025 | |
| ILMN Illumina | Maintains: Equal-Weight | $100 → $105 | $100.92 | +4.04% | 9 | Aug 4, 2025 | |
| AVTR Avantor | Maintains: Equal-Weight | $15 → $12 | $12.39 | -3.15% | 20 | Aug 4, 2025 | |
| HOLX Hologic | Maintains: Equal-Weight | $65 → $69 | $63.80 | +8.15% | 10 | Jul 31, 2025 | |
| NEO NeoGenomics | Maintains: Equal-Weight | $10 → $8 | $8.08 | -0.99% | 14 | Jul 30, 2025 | |
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $9 → $7 | $3.96 | +76.77% | 9 | May 28, 2025 | |
| CYRX Cryoport | Maintains: Equal-Weight | $8 → $7 | $8.77 | -20.18% | 2 | May 5, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $7 → $9 | $13.08 | -31.19% | 12 | May 5, 2025 | |
| MRVI Maravai LifeSciences Holdings | Maintains: Equal-Weight | $7 → $5 | $2.72 | +83.82% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $39.33 | -49.15% | 2 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $176 → $185 | $172.16 | +7.46% | 13 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $245 → $250 | $185.97 | +34.43% | 11 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $647 → $678 | $474.46 | +42.90% | 14 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Equal-Weight | $24 → $23 | $26.23 | -12.31% | 1 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $28 | $31.87 | -12.14% | 13 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $7.31 | +187.28% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.20 | +66.67% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $10.27 | +289.48% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $0.77 | +674.79% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $3.17 | +215.46% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $3.15 | -12.70% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $5 | $5.93 | -15.68% | 12 | Feb 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $2.05 | +389.00% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $54.79 | +33.24% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $152.24 | +64.21% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $7.60 | +1,215.79% | 5 | May 12, 2022 |
Tempus AI
Aug 12, 2025
Maintains: Overweight
Price Target: $65 → $68
Current: $85.13
Upside: -20.12%
10x Genomics
Aug 12, 2025
Maintains: Overweight
Price Target: $18 → $17
Current: $13.35
Upside: +27.34%
Illumina
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $100.92
Upside: +4.04%
Avantor
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $12.39
Upside: -3.15%
Hologic
Jul 31, 2025
Maintains: Equal-Weight
Price Target: $65 → $69
Current: $63.80
Upside: +8.15%
NeoGenomics
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $8.08
Upside: -0.99%
Cytek Biosciences
May 28, 2025
Maintains: Equal-Weight
Price Target: $9 → $7
Current: $3.96
Upside: +76.77%
Cryoport
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $8.77
Upside: -20.18%
Adaptive Biotechnologies
May 5, 2025
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $13.08
Upside: -31.19%
Maravai LifeSciences Holdings
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $2.72
Upside: +83.82%
Mar 18, 2025
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $39.33
Upside: -49.15%
Mar 5, 2025
Maintains: Overweight
Price Target: $176 → $185
Current: $172.16
Upside: +7.46%
Feb 11, 2025
Maintains: Overweight
Price Target: $245 → $250
Current: $185.97
Upside: +34.43%
Jan 31, 2025
Maintains: Overweight
Price Target: $647 → $678
Current: $474.46
Upside: +42.90%
Dec 3, 2024
Assumes: Equal-Weight
Price Target: $24 → $23
Current: $26.23
Upside: -12.31%
Nov 18, 2024
Maintains: Underweight
Price Target: $26 → $28
Current: $31.87
Upside: -12.14%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $7.31
Upside: +187.28%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.20
Upside: +66.67%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $10.27
Upside: +289.48%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $0.77
Upside: +674.79%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $3.17
Upside: +215.46%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $3.15
Upside: -12.70%
Feb 27, 2023
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $5.93
Upside: -15.68%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $2.05
Upside: +389.00%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $54.79
Upside: +33.24%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $152.24
Upside: +64.21%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $7.60
Upside: +1,215.79%